Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000495290 | SCV000578167 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2017-06-29 | reviewed by expert panel | curation | Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02; http://priors.hci.utah.edu/PRIORS/). |
Ambry Genetics | RCV000572103 | SCV000668494 | likely benign | Hereditary cancer-predisposing syndrome | 2017-06-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Color Diagnostics, |
RCV000572103 | SCV000683020 | likely benign | Hereditary cancer-predisposing syndrome | 2016-10-29 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000466094 | SCV000717752 | likely benign | not provided | 2019-12-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001497945 | SCV001702684 | likely benign | Hereditary breast ovarian cancer syndrome | 2025-01-06 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000572103 | SCV002538103 | likely benign | Hereditary cancer-predisposing syndrome | 2020-05-06 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV003493587 | SCV004242835 | likely benign | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003493587 | SCV005887552 | likely benign | not specified | 2025-01-31 | criteria provided, single submitter | clinical testing |